eoadjuvant chemotherapy offers several benefits including breast conservation in patients with locally advanced breast cancer (LABC). 1, 2 Moreover it provides the opportunity of early recognition of chemotherapy failure or therapy success.
that may pre dict res pon se to tre at ment may be iden ti fi ed. Hor mo nal re cep tors (HR) and Her2/neu pro te in ex pres si on are ava i lab le pri mary prog nostic mar kers for tre at ment plan ning. 4, 5 Pa ti ents with es tro gen re cep tor (ER) and pro ges te ro ne re cep tor (PR) po si ti ve but Her2/ne u ne ga ti ve tu mors we re as so ci a ted with im pro ved ove rall sur vi val. 6, 7 NSABP B27 and NSABP B18 stu di es ha ve shown hig her pat ho lo gic comp le te res pon se (CR) ra tes in HR ne ga ti ve pa ti ents when com pa red to HR po siti ve pa ti ents. 8, 9 Pre o pe ra ti ve che mot he rapy may chan ge HR and Her2/ne u ex pres si ons in the fi nal sur gi cal spe ci men. 10, 11 The sig ni fi can ce of this change is unc le ar. We ret ros pec ti vely in ves ti ga ted the fre qu ency of HR and Her2/ne u sta tus chan ge in res pon se to ne o ad ju vant che mot he rapy.
MA TE RI AL AND MET HODS
Bet we en May 1999 and No vem ber 2007, 49 pa tients with LABC (sta ge IIB, II I A, II IB and II IC) trea ted with ne o ad ju vant che mot he rapy we re ret ros pec ti vely eva lu a ted. Me di an age at di ag no sis was 53 ye ars (ran ge, 27-79). Me di an Eastern cooperative oncology group (ECOG) per for man ce status of the pa ti ents was 0 (ran ge, 0-2). Pa ti ent cha rac te ris tics are shown in Tab le 1.
Pret re at ment his to lo gic con fir ma ti on of the inva si ve tu mor was per for med by co re ne ed le bi opsy for all pa ti ents. Af ter sur gery, HR and Her2/ne u status we re iden ti fi ed on the mas tec tomy spe ci mens. Thirty-thre e pa ti ents re ce i ved thre e or fo ur cycles of ne o ad ju vant che mot he rapy with do ce ta xel 75 mg/m² and epi ru bi cin 75 mg/m² (TE). Six te en pa tients re ce i ved three or four cycles of do xo ru bi cin 60 mg/m 2 plus cyclop hosp ha mi de 600 mg/m 2 plus 5-flu o ro u ra cil 600 mg/m 2 (CAF). Her2/ne u-po si ti ve pa ti ents did not re ce i ve tras tu zu mab tre at ment. All pa ti ents un der went mo di fi ed ra di cal mas tec tomy or bre ast con ser ving sur gery af ter ne o ad ju vant tre atment. Af ter sur gery, all pa ti ents re ce i ved two or three cycles ad ju vant che mot he rapy with the sa me re gi mens to comp le te six cycles. In ad di ti on, pa tients we re gi ven ra di ot he rapy when ap prop ri a te. All HR-po si ti ve pa ti ents re ce i ved en doc ri ne the rapy.
ER and PR we re con si de red po si ti ve if mo re than 10% of the tu mors cells sho wed nuc le ar immu no his toc he mi cal (IHC) sta i ning. Her2/ne u IHC 3+ or flu o res cen ce in si tu hybri di za ti on (FISH) po si ti vity we re con si de red as po si ti ve. Pre-and posttre at ment HR and Her2/ne u ex pres si ons we re re cor ded. Chan ges in HR and Her2/ne u sta tus were eva lu a ted in terms of res pon se to ne o ad ju vant tre at ment and sur vi val.
In sta tis ti cal analy sis, SPSS for Win dows 11.5 was used. McNe mar test was used to eva lu a te the pa i red cor re la ti on bet we en HR and Her2/ne u expres si ons be fo re and af ter ne o ad ju vant che mot herapy. Ob jec ti ve res pon se ra tes we re com pa red using Fis her exact test. The di se a se-fre e sur vi val 
RE SULTS
Chan ges in HR and Her2/ne u sta tus af ter ne o ad juvant che mot he rapy are presented in Tab le 2. Ne oad ju vant che mot he rapy had no ef fect on ER or PR ex pres si on in 35 pa ti ents (71%). Po si ti ve ER expres si on was iden ti fi ed in 28 (57.1%) and 32 pa tients (65.3%) be fo re and af ter ne o ad ju vant che mot he rapy, res pec ti vely (p=0.375). Po si ti ve PR ex pres si on was de tec ted in 17 (34.7%) and 25 pa tients (51.0%) be fo re and af ter ne o ad ju vant che mothe rapy, res pec ti vely (p= 0.109). Two PR po si ti ve pa ti ents lost the ir PR ex pres si ons (4%) fol lo wing ne o ad ju vant che mot he rapy. In ad di ti on, two (4%) pa ti ents with po si ti ve Her2/ne u be ca me Her2/ne u ne ga ti ve af ter ne o ad ju vant che mot he rapy.
Twel ve (24%) pa ti ents with ne ga ti ve ER and PR ex pres si ons we re con ver ted to po si ti ve af ter neo ad ju vant che mot he rapy. The se 12 pa ti ents we re furt her analy zed for res pon se ra tes, DFS and OS. Me di an fol low up was 56 months (ran ge, 32-98). Ove rall res pon se ra te (ORR) was 69%. Cli ni cal CR was ob ser ved in three (6%), par ti al res pon se (PR) in 31 (63%) and stab le di se a se (SD) in 15 pa ti ents (31%). An ob jec ti ve res pon se was ob ser ved in nine (75%) of the 12 pa ti ents who we re con ver ted to HR-po si ti ve sta tus in con trast to the re ma i ning 37 pa ti ents with an ORR of 67% (p=0.536). Si mi larly, 5-ye ar DFS (100% vs 85%) and OS (100% vs 90%) we re not sta tis ti cally sig ni fi cantly dif fe rent bet ween the se gro ups (p= 0.921 and p=0.772, res pec tively).
DIS CUS SI ON
We ha ve in ves ti ga ted chan ges in the pat tern of HR and Her2/ne u pro te in ex pres si ons in pa ti ents with LABC tre a ted with pre o pe ra ti ve ta xa ne and/or ant hracy cli ne-ba sed che mot he rapy. We ob ser ved chan ges in 16 (32.6%) of the 49 pa ti ents. Among tho se, 12 pa ti ents ga i ned HR po si ti vity and two lost PR ex pres si on. Only two pa ti ents' Her2 sta tus chan ged to ne ga ti ve. The se re sults are in ac cor dance with the re sults re por ted in the li te ra tu re.
The is su e of chan ge in the HR and Her2 sta tus in pre-and pos to pe ra ti ve spe ci mens has be en the sub ject of va ri o us stu di es. Se ve ral stu di es ha ve shown chan ges in HR and Her2/ne u pro te in expres si on af ter ne o ad ju vant che mot he rapy. [10] [11] [12] [13] [14] [15] Ja in et al. 10 de mons tra ted ER and/or PR ex pres si on chan ge in 33% of ne o ad ju vant che mot he rapy re cipi ents. Mak ris et al. des cri bed a dec re a se in ER expres si on fol lo wing ne o ad ju vant che mot he rapy.
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In te res tingly, this was cor re la ted with tu mor respon se. Pi per et al. similarly re por ted 26% in ci dence of chan ge in ex pres si on of HR and Her2/ne u af ter ne o ad ju vant che mot he rapy com pa red to only 6% in tho se who did not get any tre at ment in betwe en. 12 In anot her study, Le e et al. re por ted that 61% of the study po pu la ti on had al te ra ti ons of preand post che mot he rapy ER and/or PR ex pres sions. 13 The re are se ve ral stu di es sho wing that HR status may chan ge in the fi nal sur gi cal spe ci men compa red to ini ti al co re bi opsy wit ho ut any con fo un ding che mot he rapy or ot her fac tors. Pi per et al. re por ted chan ges in 6% of the pa ti ents wit ho ut ne o ad ju vant in ter ven ti on. 12 Ho we ver, Le e et al. sho wed a 48% dif fe ren ce in HR ex pres si on sta tus bet we en the ini ti al co re bi opsy and fi nal pat ho logy spe ci men. 13 Ca hill et al. cla i med that ini ti al di agnos tic co re bi op si es sig ni fi cantly overs co red HR expres si on. 16, 17 Pos sib le exp la na ti ons for this va ri a ti on inc lu de tis su e samp ling er rors or tech ni cal fi xa ti on and sta i ning va ri ab les. This is su e war rants furt her in ves ti ga ti on.
Her2/ne u pro to on co gen is ove rex pres sed in ap pro xi ma tely 25% of pa ti ents with bre ast can cer. 18 Its ove rex pres si on has tra di ti o nally be en cor re la ted Turkiye Klinikleri J Med Sci 2010;30 (2) ER= estrogen receptor, PR= progesteron receptor with po or prog no sis. Many stu di es ha ve in ves ti gated the cor re la ti on bet we en Her2 ex pres si on and tu mor res pon se to ant hracy cli ne-and/or ta xa neba sed ne o ad ju vant che mot he rapy in bre ast can cer. Most of the se stu di es ha ve not re por ted a sig ni ficant cor re la ti on bet we en tu mor res pon se and Her2/ne u sta tus. 19, 20 The in tro duc ti on of tras tu zumab, an an ti-Her2 chi me ric mo noc lo nal an ti body, has chan ged the na tu ral his tory of bre ast can cer with Her2 ove rex pres si on. 21 Ho we ver, most of the stu di es in ves ti ga ting HR chan ge we re pub lis hed in the pre-tras tu zu mab era. In re cent a study, Ti ez zi et al. re por ted a sig ni fi cant as so ci a ti on bet we en DFS and OS and Her2 pro te in ove rex pres si on in bre ast can cer pa ti ents. 22 Ad di ti o nally, they re por ted no sig ni fi cant Her2/ne u ex pres si on al te ra ti on be fo re and af ter ne o ad ju vant che mot he rapy. Si mi larly, Zha o et al. and Arens et al. fa i led to de mons tra te any chan ge in Her2 sta tus with ne o ad ju vant chemot he rapy. 15, 23 Ho we ver, the re are al so conf lic ting re ports that show al te ra ti ons of Her2 sta tus. 12 In our study, the re was only 4% chan ge in Her2 sta tus with no as so ci a ti on with the tu mor res pon se.
Des pi te all the se re ports, cli ni cal re le van ce of the se al te ra ti ons in HR and Her2 sta tus has not been cle arly de mons tra ted. Li te ra tu re da ta are conflic ting on this is su e. Chan ge in ER and/or PR sta tus did not ap pe ar to af fect res pon se to tre at ment in one study, 10 but Mak ris et al. cla i med that the se alte ra ti ons we re cor re la ted with res pon se to tre atment. 11 Le e et al. re por ted that chan ges in ER and PR ex pres si ons did not chan ge ove rall HR sta tus. 13 The re was a chan ge in HR sta tus in only 5% of the pa ti ents. Si mi larly, Pi per et al. conc lu ded that these re cep tor al te ra ti ons ef fec ted only two pa ti ents (6%). 12 Anot her study from Chi na re por ted no signi fi cant dif fe ren ce in HR sta tus. 15 Fi nally, our results sho wed that the se al te ra ti ons in HR and Her2 sta tus did not ha ve any ef fect on pa ti ent sur vi val. Pos sib le exp la na ti ons for the se re sults may be insuf fi ci ent pa ti ent num ber and ab sen ce of eno ugh events to ca u se a sta tis ti cal sig ni fi can ce. Ta ken toget her the se da ta in di ca te that, alt ho ugh a mi nority of the pa ti ents are in vol ved, the re sults of mar ker analy sis in the fi nal sur gi cal spe ci men should be awa i ted for de fi ni te HR sta tus de ter mi na tion to avo id ad ver se out co me.
In conc lu si on, we ha ve in ves ti ga ted chan ges in HR and Her2/ne u ex pres si on sta tus in res pon se to ne o ad ju vant che mot he rapy. We fo und al te ra tions in HR and Her2 sta tus with no ef fect on sur vival. HR and Her2 sta tus de ter mi na ti on in the fi nal sur gi cal spe ci men is re com men ded. Cli ni cal stu dies with gre a ter num ber of pa ti ents are war ran ted.
Turkiye Klinikleri J Med Sci 2010;30 (2) 472 Kaya ve ark.
Tıbbi Onkoloji
